The 'bag of options' biotech valuation framework
The speaker presented a concept framework for valuing pre-commercial biotech companies by summing the net present values of individual clinical drug pipelines adjusted for phase transition probability base rates.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.